News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an earnings forecast for ATAI Life Sciences NV (ATAI), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 15 analysts, the average target price is $12.00, suggesting a potential upside of 48.79%. The stock currently holds …
This article provides a risk assessment for ATAI Life Sciences NV (ATAI), ranking it 99 out of 385 in the Biotechnology & Medical Research industry with a score of 4.10. Key metrics include a beta of 1.60, indicating higher volatility than the S&P 500, …
Eli Lilly (NYSE: LLY) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to the medicines everyone has heard of by now: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for …
The psychedelic medicine field looks like it's finally about to take off, and that's catching the attention of portfolio managers like Cathie Wood. Eli Lilly (NYSE: LLY) agreed on July 16 to acquire the biotech AtaiBeckley (NASDAQ: ATAI) for a $2.8 billion upfront payment, …
MONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of AtaiBeckley, Inc. (Nasdaq: ATAI) (“AtaiBeckley”) to Eli Lilly and Company (“Lilly”), pursuant to which AtaiBeckley shareholders will receive …
This article provides a valuation analysis for ATAI Life Sciences NV (ATAI), showing its current valuation score of 6.62, which ranks 316 out of 386 in the Biotechnology & Medical Research industry. It details the company's P/E ratio at -2.52, noting its position relative …
This article provides a detailed quarterly and annual income statement for ATAI Life Sciences NV (ATAI) from FY2020Q1 to FY2026Q1. It includes key financial metrics such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income/expenses, and various net income figures. …
This article details the shareholder structure of ATAI Life Sciences NV (ATAI), outlining major shareholders, their proportion of holdings, and changes over time. It also breaks down shareholder types such as family offices, investment advisors, and hedge funds, and provides institutional shareholding trends over …
This article provides historical dividend and stock split information for ATAI Life Sciences NV (ATAI). It states that ATAI has distributed a total of $0.00 in dividends over the past five years and currently has no dividend data available. The page also displays current …
This article provides a detailed analysis of ATAI Life Sciences NV (ATAI) using TradingKey's Stock Score system, highlighting its strong fundamentals, high growth potential, and very high institutional ownership. The company is in a growing phase with steady revenue and net income growth. Analysts …
This article provides a technical analysis of ATAI Life Sciences NV (ATAI), showing its current price momentum score as 6.36 and noting it ranks 25th in its industry. The stock is trading between a resistance level of $8.21 and a support level of $5.14, …
Search by ticker symbol or company name and select a result to open its chart.